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ABSTRACT
The epigenetic landscape of cancer includes both fo-
cal hypermethylation and broader hypomethylation
in a genome-wide manner. By means of a compre-
hensive genomic analysis on 6637 tissues of 21 tu-
mor types, we here show that the degrees of overall
methylation in CpG island (CGI) and demethylation
in intergenic regions, defined as ‘backbone’, largely
vary among different tumors. Depending on tumor
type, both CGI methylation and backbone demethy-
lation are often associated with clinical, epidemiolog-
ical and biological features such as age, sex, smok-
ing history, anatomic location, histological type and
grade, stage, molecular subtype and biological path-
ways. We found connections between CGI methy-
lation and hypermutability, microsatellite instability,
IDH1 mutation, 19p gain and polycomb features, and
backbone demethylation with chromosomal instabil-
ity, NSD1 and TP53 mutations, 5q and 19p loss and
long repressive domains. These broad epigenetic
patterns add a new dimension to our understanding
of tumor biology and its clinical implications.
INTRODUCTION
Epigenetic alterations have pivotal roles in development and
cancer biology (1,2). A canonical observation in many can-
cers is the de novo methylation of CpG islands (CGIs) in
the promoters of tumor-related genes, which is significantly
associated with clinical behavior in many tumors. Tumors
with CGI methylation in multiple genes were often referred
to as CpG island methylator phenotype (CIMP) but the
definition varied among different tumors (3,4). Aside from
this specific subtype, it is increasingly recognized that can-
cer cells show global demethylation of large intergenic and
repeat regions and have large hypomethylated blocks largely
overlapping across different tumor types (2,5–8). Studies on
such demethylated tumors are however limited to sporadic
reports on cell-lines or small patient series due to the limi-
tation of conventional assays.
Recent genomic techniques enabled examination on such
unnoticed regions. Whole genome bisulfite sequencing
(WGBS) will be the best method to investigate the inter-
genic region; however, its utility is hampered by high cost
and analytical burden. DNA methylation arrays can be a
good alternative to investigate genome-wide methylation
among a large collection of tumors. Such arrays have probes
densely positioned for CGI and promoter regions but also
have probes sparsely embedded for intergenic regions, and
therefore, the comprehensivemethylome can be investigated
through a careful statistical approach.
This study was motivated and expanded from our pre-
vious work on B-cell acute lymphoblastic leukemias (7),
in which WGBS and methylation array analyses indicated
two-track methylation changes for ‘potentially functioning’
sites including CGIs, CGI shores, promoters, 5′-bodies, ex-
ons, DNase hypersensitive sites (HS), transcription factor
(TF)-binding sites and enhancer sites which behave dif-
ferently from other ‘relatively non-functioning’ intergenic
sites. For example, many CGIs and DNase HS were de novo
methylated in sharp contrast to the frequent demethylation
of intergenic regions. TF-binding sites behaved differently
according to TF contents; the binding sites of embryonic
stem cell (ESC)-related TFs including polycomb proteins
and CTBP2 were frequently de novo methylated while the
binding sites of other differentiation-associated TFs were
rather demethylated or unchanged. In this regard, we par-
titioned such regions and defined the ‘backbone’ as the re-
mainder of the genome corresponding to neither of those
functional sites nor repeat sequences; such repeat sequences
were also excluded because of observed technical and sta-
tistical problems. As the backbone may represent the non-
functional sites where the vast majority of human CpGs
are located, we could assess genome-wide demethylation in
tumor cells in comparison with the de novo methylation in
small functional sites, especially in CGIs. The partitioning
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and averaging also enabled us to overcome certain biases
from the unevenness of array probe design.
Adopting this strategy, we analyzed 6637 tumors in 21
tumor categories from the Cancer Genome Atlas (TCGA)
project. The two-track epigenetic changes, represented as
CGI methylation and backbone demethylation, were evi-
dent in most tumors but the degrees varied among different
tumors. More importantly, the degrees of abnormal methy-
lation correlated with certain biological and clinical charac-
teristics. Such associations, especially regarding demethyla-
tion, are as yet largely unexplored and thus the current study
may provide insights to biologists and clinicians interested
in each tumor type.
MATERIALS AND METHODS
Subjects and tumor types
Genomic data and clinical information of 6637 tumor and
700 adjacent normal tissues of 21 tumor types was re-
trieved from the TCGA data portal (Supplementary Ta-
ble S1). The 21 tumor types include adrenocortical carci-
noma (ACC), bladder urothelial carcinoma (BLCA), breast
invasive carcinoma (BRCA), cervical squamous cell carci-
noma and endocervical adenocarcinoma (CESC), colorec-
tal adenocarcinoma (COADREAD), glioblastoma multi-
forme (GBM), head and neck squamous cell carcinoma
(HNSC), kidney chromophobe (KICH), kidney renal clear
cell carcinoma (KIRC), kidney renal papillary cell car-
cinoma (KIRP), acute myeloid leukemia (LAML), brain
lower grade glioma (LGG), liver hepatocellular carcinoma
(LIHC), lung adenocarcinoma (LUAD), lung squamous
cell carcinoma (LUSC), prostate adenocarcinoma (PRAD),
skin cutaneous melanoma (SKCM), stomach adenocarci-
noma (STAD), thyroid carcinoma (THCA), uterine corpus
endometrial carcinoma (UCEC) and uterine carcinosar-
coma (UCS).
Retrieval and processing of methylation data
For methylation, we obtained level 2 data of the In-
finium HumanMethylation450 array (Illumina) containing
background-corrected methylated and unmethylated sum-
mary intensities and beta values as extracted by the methy-
lumi package. Type 1 and 2 probe adjustment was done us-
ing the beta-mixture quantile normalization (BMIQ)model
implemented in the R software ChAMP package. A super-
vised batch correction using the ComBat algorithm was
done by integrating all the 6637 methylation array data
and incorporating batch and array ID information. Probes
having a common single nucleotide polymorphism (SNP)
(minor allele frequency > 1% as defined by the UCSC
snp135common track) within 10 bp of the interrogated
CpG site or having 15 bp from the interrogated CpG site
overlap with a repeat element (as defined by the Repeat-
Masker) were masked across all samples, and probes with
a non-detection probability (P-value) greater than 0.05 in
a given sample are also masked. CpGs in sex chromosomes
were excluded. We also downloadedWGBS data of 40 sam-
ples from the TCGA data portal, and 14 among them had
methylation array data.
Downloading and processing other genomic data
For other genomic data, normalized gene expression
(RSEM) values from RNA sequencing, microRNA
(miRNA) expression values from miRNA sequencing,
calculated segmentation values from the Genome-Wide
Human SNP 6.0 array (Affymetrix), and validated muta-
tion calls from exome, RNA and whole genome sequencing
were obtained from the Broad Genome Data Analysis
Center (GDAC) Firehose server as processed and normal-
ized by its pre-established pipeline (version 04–16–2014;
doi:10.7908/C16W9975) (Supplementary Table S1). Sec-
ondary analysis data were all downloaded from the Broad
GDAC Firehose server (version 04–16–2014), including
clustering information of DNA methylation, RNA ex-
pression, miRNA expression and somatic copy number
alteration (SCNA) by the cNMF algorithm (best clusters
by the cNMF algorithm were adopted for further analysis),
significantly-mutated genes by the MutSig algorithm,
significant SCNA peaks and arm- and gene-level copy
changes by the GISTIC algorithm, and pathway activities
inferred from RNA expression and SCNA data by the
PARADIGM algorithm. Using the SCNA segmentation
data downloaded from the GDAC Firehose server, we
further calculated tumor purity and ploidy estimates by the
ABSOLUTE software package (9).
Region definition and calculation
Annotations on CGIs, reference genes (RefSeq gene), ex-
ons, DNase hypersensitive site clusters, consensus binding
sites of 161 TFs from the chromatin-immunoprecipitation
data by the ENCODE project, Vista enhancer sites, and re-
peat regions (defined by RepeatMasker) were downloaded
from the USCS genome server. CGI shore was defined as ±
2 kb region from the CGI boundary. Promoter was defined
as 0–1.5 kb upstream region of transcription start site and
5′-body was defined as 0–0.1 in fractional region of gene
body. We excluded all these defined regions and designated
the remainder region as ‘backbone’. Lamina-associated do-
mains (LADs) of lung fibroblasts and FSU Repli-chip data
of eight cell-lines were also downloaded from the USCS
genome server. Information on partially methylated do-
mains (PMDs) of a colon cancer cell-line and placenta, and
LADs of cultured B-lymphoblasts was obtained from previ-
ous studies (10–12). Definition on 199 chromatin-modifier
genes was introduced from a curated list by Gonzalez-Perez
et al. (13).
Clinical and pathological parameters
Clinical and pathological parameters analyzed in each tu-
mor type are listed in Supplementary Table S2. All gradable
variables including stage, histological grade, immunohisto-
chemical stain intensity, Gleason score, Karnofsky score
and ECOG performance grade were converted to numeric
factors for further analysis. Smoking history graded by
pack/year, anatomical locations ordered according to di-
gestive and airway tracts, microsatellite instability (MSI)
graded asmicrosatellite-stable (MSS), intermediate (MSI-I)
and high (MSI-H), and primary treatment response graded
as complete response, partial response, stable disease and
 at Y
O
N
SEI U
N
IV
ERSITY
 M
ED
ICA
L LIBRA
RY
 on O
ctober 16, 2016
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
Nucleic Acids Research, 2016, Vol. 44, No. 3 1107
progressive disease were also converted into numeric fac-
tors. Categorical variables were coded as dummy variables.
A multivariate linear model controlling age and gender was
used wherever applicable. A Kaplan-Meier survival analy-
sis was performed to assess implication on clinical outcome.
By reviewing literature and considering the availability of
information in TCGA data set, clinical, pathological and
molecular variables having well-known impact or being re-
peatedly suggested in previous studies were included in a
multivariate Cox proportional hazards regression model in
each tumor type.
Molecular parameters
DNA methylation, RNA expression, miRNA expression
and SCNA clusters were identified by the cNMF algorithm
in the Firehose GDAC server and coded as dummy vari-
ables. Significantly mutated genes identified by the MutSig
algorithm (Supplementary Table S3) were selected and the
presence and absence of mutation in each gene was coded
as binomial variables for further analysis. For copy num-
ber analysis, log2ratios of 24 174 genes, 39 arms of auto-
somal chromosomes, and significant chromosomal loci in
each tumor type were identified by the GISTIC algorithm
(Supplementary Tables S4 and S5) and coded as continuous
variables. Association of molecular parameters with aver-
age CGI and backbone methylation levels were analyzed by
the Wilcoxon rank-sum test for binomials, Kruskal-Wallis
test for categorical variables, and Kendall rank correlation
test for continuous variables. In every analysis, Benjamini-
Hochberg correction by the number of comparisons (e.g. 24
174 for gene-level SCNA association) was performed.
Differentially methylated CpGs and TF enrichment
For 12 tumor types with sufficient number of normal tissue
data, we analyzed differentially methylated CpGs (defined
by methylation change >0.2 compared to mean of normal
tissues) in each sample. Using the 161 ENCODE TF bind-
ing sites, enrichment rates were calculated for each TF using
the following equation:
Enrichment rate =
(n. of differentially methylated CpGs inside TF sites)/(n. of CpGs inside TF sites)
(n. of differentially methylated CpGs outside TF sites)/(n. of CpGs outside TF sites)
RESULTS
Characterization of genome-wide average methylation
The subjects comprise 6637 tumor and 700 adjacent normal
tissues with Illumina 450k methylation array data available
from the TCGA database (Supplementary Table S1). After
filtering out sex chromosome CpGs and redundant CpGs
around SNP and repeat regions, we selected a total of 136
186 CpGs in CGI and averaged their methylation levels for
each tumor. Likewise, we selected 49 277 CpGs in back-
bone, as defined above, and averaged their methylation lev-
els for each tumor. To confirm the validity of our definition
on backbone and calculations of average methylation, we
compared averages calculated by array with averages calcu-
lated by WGBS from 14 subjects from TCGA and found a
good correlation (r = 0.840). We further estimated tumor
purities by the ABSOLUTE algorithm and found that the
methylation changes are not strongly affected by purity bi-
ases (Supplementary Figure S1).
Figure 1 is a density plot generated by the average methy-
lation of all CGI CpGs (y-axis) and average methylation of
all backbone CpGs (x-axis) in each sample. Normal tissues
maintained their CGIs hypomethylated and backbones hy-
permethylated within narrow ranges (0.18–0.24 and 0.78–
0.82, respectively) whereas tumor cells displayed variable
degrees of CGI methylation and backbone demethylation
(Figure 1A and B; Supplementary Figure S2). Consid-
ering the normal ranges, we defined high CGI methyla-
tion (HC; average CGI methylation >0.24), as opposed to
normal CGI methylation (NC; average CGI methylation
≤0.24), and low backbone methylation (LB; average back-
bone methylation <0.78), as opposed to normal backbone
methylation (NB; average backbone methylation ≥0.78).
In Figure 1C, the location of the tumor name represents
the median of cases in each tumor type, showing a wide
variety of case distribution according to tumor type. The
vast majorities of THCA, KICH, KIRP and KIRC cases
maintained CGI and backbone within normal methylation
ranges (NC-NB; Figure 1D) whereas many LGG tumors
showed deviation to CGImethylation (HC-NB; Figure 1E).
Nonetheless, most tumors showed both CGI methylation
and backbone demethylation with variable degrees (HC-
LB; Figure 1F; Supplementary Figure S2). Medians of
BLCA, UCS and LIHC were more skewed to backbone
demethylation.
Tumor-specific association
BothCGI and backbonemethylation correlated very signif-
icantly with DNA methylation clusters supporting the va-
lidity of our approach. And in most tumors, DNA methy-
lation correlated with mRNA expression, miRNA expres-
sion, copy number and pathway clusters suggesting an un-
derlying biological background. Among the epidemiolog-
ical, clinical, pathological and molecular parameters ana-
lyzed (Supplementary Tables S2–S5), those showing signif-
icant associations are exemplified in Figure 2 and outlined
in more detail in Supplementary Figures S4–S24; presenta-
tion order is according to the deviation from normal zone
(NC-NB, HC-NB and HC-LB) in Figure 1C.
Epidemiology
The CGI and backbone methylations correlated with age (r
= +0.064 and –0.230, respectively), with different degrees
according to tumor type (Supplementary Figure S3). The
methylation levels also had a slight correlation with gender
in a set of tumors (Supplementary Table S6). Accordingly,
we controlled age and gender in the following analyses on
clinical and pathological parameters.
Smoking history was significantly associated with back-
bone demethylation in LUAD with current smokers being
the most demethylated (P = 1.4 × 10−3). In THCA, histo-
ries of lymphocytic thyroiditis significantly correlated with
high CGI methylation (P = 6.3 × 10−4). In STAD, those
with very high CGI methylation were not MSI-H (Fig-
ure 2B) and supposed to be the Epstein-Barr virus (EBV)
type as suggested by a previous TCGA study (14).
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Figure 1. Distribution of genome-wide average CGI and backbone methylation in normal and tumor tissues. (A) Normal adjacent tissues have average
CGI methylation around 0.2 and average backbone methylation around 0.8 within narrow limits. (B) Tumor cells have variable degrees of CGI methylation
and backbone demethylation. (C) The distributions of abnormal methylations according to tumor types. Tumor names are presented at median levels of
CGI and backbone methylation in each tumor type. (D) THCA cases are distributed mostly in normal ranges (NC-NB). Abbreviations: NC, normal CGI
methylation (≤0.24); HC, high CGI methylation (>0.24); NB, normal backbone methylation (≥0.78); LB, low backbone methylation (<0.78). (E) LGG
cases are distributed mostly in the CGI-methylated zone (HC-LB). (F) Most of COADREAD cases are both CGI-methylated and backbone-demethylated
with variable degrees.
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Figure 2. Exemplary tumors showing remarkable association with clinical, pathological and molecular parameters. (A) KICH tumors higher CGI methy-
lation are related with advanced pathological stage, high grade, chromosome 9 loss, high mutation rate, SETD2 and BAP1 mutations, and low activities
of FoxM1, Aurora B and PLK1 pathways. (B) STAD tumors with higher CGI methylation are related with high histological grade, high microsatellite
instability (MSI-H), gains of 9p and 19p, high mutation rate, PIK3CA and ARID1A mutations, and low activities of p75NTR, Reelin and Ret pathways.
(C) STAD tumors with lower backbone methylation are associated with low histological grade, non-diffuse type, low pathological stage, higher number
of somatic copy number alterations (SCNAs), loss of 19p and 5q11, gain of 1q21, TP53 mutation, and low activities of c-Kit, FoxM1 and p53 pathways.
(D) In LGG, backbone demethylation is associated high histological grade, astrocytoma histology, temporal lobe location, high number of SCNAs, loss
of chromosome 10, gain of chromosome 7, EGFR and PTEN mutations, and low activities of BMP receptor, Ret and EGFR pathways.
Anatomic location
In COADREAD, CGI methylation was highest in cecum
tumors and became modest when moving towards the rec-
tum (P = 1.3 × 10−16; Supplementary Figure S25A). In
HNSC, CGI methylation was highest in the oral cavity and
lower in the caudal direction in the oropharangeal tract (P
= 8.9× 10−5; SupplementaryFigure S25B). InLGG, higher
CGI methylation was observed in frontal lobe tumors and
lower backbone methylation in temporal lobe tumors (P =
5.1 × 10−6 and 1.1 × 10−3, respectively).
Histology and stage
Methylation status often correlated with histological sub-
types in part reflecting their difference in cell composition.
Follicular THCA had slightly higher CGI methylation than
papillary THCA (P= 2.3× 10−3). Undifferentiated LAML
and LAML without maturation (M0 and M1 by the FAB
classification, respectively) had higher CGI methylation (P
= 4.5× 10−4), andmonocytic LAML (M5) had lower back-
bone methylation (P = 1.2 × 10−5). In LGG, oligoden-
drogliomas displayed very high CGI methylation while as-
trocytomas showed backbone demethylation (P = 2.2 ×
10−6 and 5.7 × 10−4, respectively). In CESC, adenocarci-
noma had mostly high CGI methylation (P = 2.7 × 10−9).
Intestinal and non-diffuse type STADswere associatedwith
lower backbone methylation (P = 1.7 × 10−5) (Figure 2B).
Endometrioid UCEC had both CGImethylation and back-
bone demethylation (P = 1.4 × 10−12 and 1.7 × 10−2, re-
spectively). Type 2 KIRP, an eosinophilic tumor with worse
prognosis, was associated with both CGI methylation and
backbone demethylation (P = 4.4 × 10−5 and 1.9 × 10−3,
respectively).
Higher histological grade was significantly associated
with higher CGI methylation in KIRC, STAD and BLCA
(P = 1.5 × 10−6, 2.5 × 10−2 and 2.8 × 10−2, respectively)
and with lower backbone methylation in LGG (P = 6.9 ×
10−6) (Figure 2). In PRAD, Gleason scores tended to be
high both in CGI-methylated and backbone-demethylated
tumors (P = 6.1 × 10−3 and 3.9 × 10−4, respectively). An
association of CGI methylation with high mitosis was ob-
served in ACC (P = 4.5 × 10−4).
In many tumors including KICH, KIRP, KIRC, PRAD,
BRCA, LUAD, HNSC, ACC and UCEC, increased CGI
 at Y
O
N
SEI U
N
IV
ERSITY
 M
ED
ICA
L LIBRA
RY
 on O
ctober 16, 2016
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
1110 Nucleic Acids Research, 2016, Vol. 44, No. 3
methylation was associated with advanced stages. In
THCA, KIRP, KIRC, BRCA, SKCM, and UCS, decreased
backbone methylation was also associated with advanced
stages.
Molecular subtype
As examined by conventional diagnostic tests, some molec-
ular subtypes were associated with methylation. MSI-H tu-
mors were very significantly associated with CGI methyla-
tion in COADREAD, STAD and UCEC (P= 3.2 × 10−12,
2.4 × 10−7 and 2.0 × 10−22, respectively) (Figure 2B). In
COADREAD, CGI methylation was associated with neg-
ative expression of MSH6 and PMS2 proteins (P = 9.3 ×
10−3). In BRCA, CGI methylation was significantly asso-
ciated with positive expression of estrogen and HER2/neu
receptors (P= 1.5 × 10−5 and 8.3 × 10−8, respectively) and
thus with luminal B subtype (P = 1.3 × 10−9).
Gene mutation
The number of gene mutations correlated positively with
CGI methylation in THCA, KIRC, LAML, LGG, GBM,
PRAD, STAD, BRCA, ACC and UCEC (Figure 2A and
B). In line with the previous knowledge, IDH1 mutation
was associated with high CGI methylation in LGG (P =
2.1 × 10−20), GBM, PRAD and CESC, and IDH2 was so
in LAML. Mutations in CIC, NOTCH1 and FUBP1 were
very significantly associated with high CGI methylation in
LGG (P = 5.7 × 10−11, 5.2 × 10−7 and 9.9 × 10−5, re-
spectively), mutation in PIK3CA was so in STAD (P = 7.4
× 10−9), and mutations in PTEN and PIK3R1 were so in
UCEC (P= 5.9× 10−7 and 1.6× 10−4, respectively).NRAS
mutation was frequent in THCA with higher CGI methy-
lation and BRAF was so in THCA with lower backbone
methylation (P = 5.9 × 10−3 and 9.9 × 10−7, respectively)
but this may be confounded by the difference in methyla-
tion according to histological type, as described above, and
high frequency of NRAS mutation in follicular and BRAF
mutation in papillary types (15).
TP53 mutation was associated with backbone demethy-
lation in STAD and PRAD (P= 5.1× 10−5 and 4.9× 10−3,
respectively) (Figure 2C), and NSD1 mutation was so in
HNSC (P= 3.2 × 10−9) (Supplementary Figure S17B). We
also observed that a high number ofmutations in chromatin
modifier genes is related with more backbone demethyla-
tion (Figure 3E).
Somatic copy number alteration
High number of SCNA significantly correlated with low
backbone methylation in LGG, PRAD, COADREAD,
STAD, BRCA, LUAD, HNSC, SKCM, LUSC, BLCA and
LIHC (Figure 2C andD). In Supplementary Figures S4–25,
we presented chromosomal bands and arms showing sig-
nificant correlations with methylation in each tumor. The
most remarkable was the association of chr10 loss and chr7
gain with backbone demethylation (P< 1.0× 10−35 and 3.5
× 10−13, respectively) and 1p loss and 19q loss with CGI
methylation (P= 2.1× 10−28 and 7.6 × 10−26, respectively)
in LGG (Supplementary Figure S9).
To narrow down loci showing significant impact on
methylation repeatedly in different tumor types, we per-
formed a Kendall rank correlation test between gene-level
copy number (log2ratio) and methylation for each tumor
type. Corrected P values of individual genes were plotted
as ordered by chromosomal positions of the genes, and the
10th, 20th, 30th and 40th percentile P values among the
21 tumor types were illustrated in the plot (Supplementary
Figures S26 and S27). The most remarkable P value peak
was in chromosome 5q showing recurrent correlations be-
tween deletion and backbone demethylation in many tu-
mors (Figure 3A and B). Candidate genes in this region in-
clude CHD1, LMNB1, KDM3B, HDAC3 and NSD1, and
among them, NSD1 was of particular interest in that mu-
tation in this gene also showed the most significant asso-
ciation with backbone demethylation in HNSC and other
tumors (Figure 3C). Bi-allelic aberration of NSD1 either
by mutation or copy loss showed more demethylation (Fig-
ure 3D). Chromosome 19p was also intriguing in that loss
of this region was associated with backbone demethyla-
tion and gain was so with CGI methylation (Supplemen-
tary Figure S28). Chromatin modifier genes are densely lo-
cated at 19p, and candidate genes include SIRT6, KDM4B,
LMNB2,MBD3 and many others.
Gene expression and biological pathways
In contrast to the negative correlation between CGI methy-
lation in promoter and gene expression, backbone methy-
lation in gene body was positively correlated with expres-
sion suggesting a role of hypomethylation in gene suppres-
sion (Supplementary Figure S29). Such correlations were
less prominent in relatively silent tumors such as THCA,
KICH, KIRP, KIRC and LAML.
In Supplementary Figures S4–S24, we illustrated the top
100 PARADIGM pathways significantly correlated with
methylation along with the name of the pathway superfam-
ily having a large proportion in the top pathways. Among
the pathways recurrently associated in several tumors, the
bone morphogenic protein (BMP) receptor pathway was
significantly suppressed among backbone-demethylated tu-
mors in LGG, PRAD and LIHC and CGI-methylated tu-
mors in LUAD. Significant associations of low lysophos-
phatidic acid (LPA) receptor pathway activities with back-
bone demethylation were noted in UCEC, SKCM, BLCA
and LIHC, while with CGI methylation in BRCA. The
Ephrin B pathway was suppressed in association with back-
bone demethylation (PRAD, BRCA, SKCM and LIHC) or
CGI methylation (HNSC and UCEC). The FoxM1 path-
way activity was low in associationwith backbone demethy-
lation (STAD and LUAD) or CGI methylation (KIRP and
KIRC), whereas its activity was high in CGI-methylated
KICH tumors. Mitotic kinase pathways including polo-like
kinase 1 (PLK1), Aurora A and B pathways are suppressed
in association with backbone demethylation (KIRP and
PRAD) and CGI methylation (KIRC), while they were ac-
tive in backbone demethylated LUAD and CGI-methylated
KICH tumors. Neurotrophic factor and p75NTR pathways
were significantly suppressed only among CGI-methylated
tumors in THCA, LAML, STAD, BRCA and HNSC.
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Figure 3. Relation of copy number and somatic mutation with methylation change. (A) By concatenating gene-level associations, copy change at 5q is
found to be the most recurrently associated region with backbone demethylation. Color gradients are according to the percentiles of 21 tumor types.
Chromatin modifier genes in chromosome 5 are presented. (B) Copy loss of NSD1 at 5q35.2 is significantly correlated with backbone demethylation.
All types of tumors analyzed together and copy-neutral tumors were removed from the plot. (C) NSD1-mutated tumors show significant genome-wide
backbone demethylation (P = 1.9 × 10−11). (D) Bi-allelic NSD1 aberration by mutation and/or copy loss shows more profound demethylation (P < 2.2
× 10−16). (E) With increasing number of chromatin modifier mutation, more backbone demethylation is apparent (P < 2.2 × 10−16).
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Transcription factors
We also analyzed differential methylation in 12 tumor types
with the availability of normal control data. In all tu-
mor types, differentially methylated CpGs were highly en-
riched in binding sites of polycomb-related SUZ12, EZH2
and CTBP2, and the enrichment rate strongly correlated
with the degree of CGImethylation (Supplementary Figure
S30). Demethylated CpGs were often enriched in IKZF1,
BATF and ZNF217 binding sites but the enrichment rate
usually did not correlate with the degree of backbone
demethylation, suggesting a minor role of transcription
factors in the genome-wide demethylation (Supplementary
Figure S31).
Large demethylation domains
In most tumors, profound demethylation was noted in ge-
nomic regions that largely overlap with long repressive do-
mains, including PMDs, LADs and late-replicating regions,
as previously identified in cancer and normal cultured cells
(10,11,16). These regions were generally coincident among
different tumor types (Figure 4A). When LADs were used
as surrogates for these regions, both backbone demethyla-
tion and CGI methylation were more pronounced within
LADs (Figure 4B and C; Supplementary Figures S32 and
S33).
Clinical outcome
As to primary treatment success, backbone demethylation
was associated with poor response in LGG (P= 1.6× 10−3)
and CGI methylation was so in ACC (P = 6.7 × 10−3). In-
triguingly, CGI-methylated tumors showed better primary
responses in STAD and LUAD (P = 7.5 × 10−3 and 1.8
× 10−2, respectively). In an unadjusted survival analysis,
the HC group defined above was associated with poor sur-
vival in THCA, KICH, KIRP, KIRC and ACC. The LB
group was associated with poor survival in THCA, KICH,
KIRP and LGG, whereas intriguingly with favorable out-
come in COADREAD (Supplementary Figures S34–S41).
However, the associationsmay be largely confounded by the
frequent connection of abnormal methylation with stages
and other histopathological features, as mostly insignifi-
cant in the Cox proportional hazard models (Supplemen-
tary Figures S34–S41). In addition to the well-known fact
that LGGs with CGI methylation shows better survival, we
found that those with backbone demethylation show worse
survival even though they had high CGI methylation (i.e.
HC-LB tumors in Figure 1D and Supplementary Figure
S38).
DISCUSSION
Previous studies on cancer epigenetics have mostly focused
on CpGs in promoters and CGI where methylation has
great impact on gene expression. The definition of CIMP
and its associated CpGs varied among different studies
without clear consensus (3,4). Our approach was to aver-
age all CGIs in nearly 20 thousand genes wherever appli-
cable while finding that direct comparison with the previ-
ous CIMP classification was impossible due to the wide
heterogeneity of CIMP definition and assay method. For
pan-cancer comparison, we rather set a fixed cutoff (0.24
for CGI) inferred from methylation ranges of normal tis-
sues and then defined HC and NC that simply indicate two
groups ‘outside’ and ‘within’ the normal range. Even so,
the HC-tumors may largely overlap with the CIMP tumors
by other previous definitions. As supporting evidence, we
could observe correlation of HC-tumors with many CIMP-
associated features such as MSI-H and IDH1 mutation
(3,4).
A possible link between CGI methylation and high mu-
tation rate has been suggested with a theory that methyl-
cytosine can be a site for the C-to-T transition (3,4,17). In
this study, we found this could be extended and applied to
many other tumors. As some studies showed associations
of CIMP with stage, often with advanced and occasionally
with earlier stages (18,19), we could observe associations be-
tween CGI methylation and stage in many previously un-
investigated tumors. The association with histological type
and grade may be intriguing since it remained unexplored
in many tumors.
Polycomb site methylation has now been accepted as a
hallmark of cancers, and so the enrichment of polycomb
proteins, SUZ12 and EZH2, should be an innate quality.
The co-enrichment of CTBP2 is quite new and interesting in
that it is linked to the bivalent mark of ESC (7) and could be
a novel candidate for targeted therapy in addition to other
polycomb proteins.
Global demethylation in repetitive elements has been sug-
gested in many cancers and yet a systematical analysis is
lacking (20,21). We removed repeat regions in the back-
bone definition due to technical and statistical issues, and
nonetheless, the methylation in the backbone may at least
in part reflect that in repeat regions since the two regions
share many epigenetic properties (20,22). The examination
of backbone methylation using array data was supposed to
be valid since we observed a good concordance between the
array andWGBS calculations and also found a study adopt-
ing a similar strategy with ours (12).
Associations of demethylation with histological grade
and stage have been suggested in several tumors (23), and
we could find such an association in an expanded set of tu-
mors. Associations with histological type in THCA, KIRP,
LAML, LGG, UCEC, and STAD have not been described
before. The association of backbone demethylation with
cigarette smoking in LUAD is intriguing since many pre-
vious studies on smoking have focused on promoter CpGs
and have shown conflicting results (24–26). We have investi-
gated non-promoter regions, and in line with our results,
associations of smoking with demethylation in LINE el-
ements of aero-digestive mucosa (27), esophageal mucosa
(28) and blood cells (29) have been reported.
Although it has been experimentally shown that
demethylation is linked to mitotic dysfunction and
genomic rearrangement and anticipated to cause chromo-
some instability, it remained uninvestigated in clinical series
(21,23,30–32). Here we have presented strong statistical
evidences that higher number of SCNA correlates with
backbone demethylation in many tumors. The correlation
with SCNA was often remarkable in specific chromosomal
bands and arms, and we could find some previous literature
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Figure 4. Backbone demethylation in large genomic regions. (A) In an exemplary chromosome (chr10) demethylation is profound in large genomic regions
that overlap with partially-methylated domains (PMDs), lamina-associated domains (LADs) and late-replicating regions. Values are averaged within each
sliding window (2Mb bin and 1Mb step). (B andC) When all tumors are analyzed together, high degrees of backbone demethylation and CGImethylation
are observed inside LADs.
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Figure 5. Comprehensive model for CGI methylation and backbone
demethylation.
showing consistent results with ours such as associations
with chromosome 9 loss in BLCA (33,34), 8q gain in
PRAD (35) and 16p gain in BRCA (36).
In both gene-level copy number and mutation analy-
ses, NSD1 abnormalities were significantly associated with
backbone demethylation. NSD1 is a SET domain his-
tone methyltransferase that primarily dimethylates histone
H3K36, implicated in Sotos and Weaver overgrowth syn-
dromes. Interestingly, a methylome study on patients with
Sotos syndrome observed very pronounced demethylation
in the NSD1-mutated group (37). Although its carcino-
genic function is largely unknown, NSD1 is presumed to
have roles in tumorigenesis (6,38). Other candidate genes,
LMNB1 (lamin B1) at 5q23 and LMNB2 (lamin B2) at
19p13.3, are main components of nuclear lamina and play
significant roles inmaintaining LAD (39). As an experimen-
tal support, lamin B1 is shown to be depleted in senescent
cells leading to chromatin reorganization in LAD and pos-
sibly linking to aging and cancer development (40). TP53
was also among the most significant genes, and this can be
understood on the basis that TP53 mutations can directly
cause DNA demethylation (41). Moreover, TP53 plays crit-
ical roles DNA repair and maintaining genomic stability
(42) and its mutation may exhibit communal pathways with
DNA demethylation leading to chromosome instability.
It is often hypothesized that demethylation in cancer
cells can activate proto-oncogenes and thus contribute to
tumorigenesis (23). This should be true in a specific set
of genes, but as a whole, we observed that demethylation
of the backbone especially in gene body is more likely to
suppress gene expression (Supplementary Figure S29). It
may be in line with the perspective that gene body in a
highly expressed gene should be maintained hypermethy-
lated to dampen transcriptional noise and help efficient
transcription (43–45). As more supporting evidence, we
found that many pathways such as BMP receptor, LPA re-
ceptor, Ephrin B, PLK1, Aurora A and B, FoxM1, neu-
rotrophic factor and p75NTR pathways tended to be sup-
pressed rather than activated in demethylated tumors.
As the name ‘bone morphogenic protein’ already signi-
fies, BMP pathway has been implicated in the osteoblastic
phenotype of bone metastases in PRAD (46,47). We ob-
served that low BMP, especially BMP-7, activity is associ-
ated with backbone demethylation and such demethylated
tumors show aggressive features like high Gleason score
and prostate specific antigen level (Supplementary Figure
S10B). This is concordantwithmany previous studies show-
ing the protective role of BMP-7 and association of its loss
with invasive and migratory properties (46,48,49). We also
noticed that the demethylated tumors also tended to have
worse outcome although the significance varied according
to the cutoffs for average backbone methylation (data not
shown). BMP signaling pathway also has been implicated
in LGG, often with its beneficial effect on tumor inhibi-
tion and clinical course (50). We observed low BMP activ-
ity in demethylated LGGs which showed higher histologi-
cal grade and worse treatment response and survival (Sup-
plementary Figure S9B). BMP is also implicated in liver
and lung cancers (51,52) and we observed associations of
low BMP activities with backbone demethylation and CGI
methylation in LIHC and LUAD, respectively.
LPA is a bioactive phospholipid which through G
protein-coupled receptors induce various cellular responses
including cell proliferation, differentiation, morphogenesis,
cell migration, cytokine production and many others (53).
Accordingly, LPA pathway is implicated in a number of
cancers, often as pro-tumorigenic and sometimes as anti-
tumorigenic (54). In our analysis, low LPA receptor path-
way was often associated with backbone demethylation. In-
terestingly, these tumors showed more profound demethy-
lation than other tumors (Figure 1C) with relatively weak
or negligible associations of the demethylation with tu-
mor aggressiveness. Eph receptors and their Eph receptor-
interacting (Ephrin) ligands have been implicated in a num-
ber of tumors with dichotomic effects that both increased
and decreased activities are linked to tumor progression
(55). We observed that Ephrin pathways are epigenetically
suppressed in a set of tumors preferentially by backbone
demethylation.
Mitotic kinases including PLK1 and Aurora kinase have
unique roles in mitosis and their overexpression has been
suggested to be associated with invasiveness and chromo-
some instability in many tumors (56). We found that PLK1
and Aurora pathways are often suppressed and sometimes
activated in backbone-demethylated or CGI-methylated tu-
mors. It is notable that the pathways also act as mitotic
bodyguards for confident cell division (57) and a low ac-
tivity can also lead to chromosome instability (56). The
FoxM transcription factors, targeting cell cycle regulators
like cyclins, PLK1 and Aurora kinases, are also crucial for
cell cycle phase progression and mitosis (58). Either loss or
gain of FoxM function can alter cell fate and promote tu-
morigenesis (59), and we observed epigenetic suppression
of FoxM1 pathway in a set of tumors. Inversely, FoxM1 has
been shown to directly reshape the epigenomic landscape
of tumor cells (60). Neurotrophin and its receptor p75NTR
have critical roles in ESC pluripotency and their dysregu-
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lation has been implicated in many tumors (61). They were
specifically dysregulated in CGI-methylated tumors in our
analysis, and this may be understood in parallel with the
high enrichment of methylated CpGs in ESC-related TFs
(Supplementary Figure S30).
Through advanced genomic technologies, recent liter-
ature reports have noted that both normal and cancer
cells have long repressive domains largely overlapping with
LADs and having unique epigenetic properties (16,62).
These domains have been recognized as PMDs in EBV-
transformed cell-lines (11), normal placenta (12) and cul-
tured cancer cell-lines (10,63). Timp et al. suggested that
these regions are largely concordant across breast, colon,
lung, pancreas and thyroid cancers (8), and here we con-
firm that it is true in almost all tumors but the degrees
of demethylation in these regions vary among different tu-
mors (Figure 3). Consistent with previous studies (10,12),
we observed a paradoxically high CGI methylation in those
demethylated domains, which may in part reflect the high
overlap between backbone demethylation and CGI methy-
lation in the vast majority of tumors (Figure 1). Such high
overlaps may also explain the concomitant associations of
some parameters with both backbone demethylation and
CGI methylation.
We also observed that intra-tumoral heterogeneity may
exist with some clinical implications. For example, most
THCA tumors belonged to NC-NB tumors by our pan-
cancer cutoffs, and however, two clusters with slightly-high
and slightly-low CGI methylation existed even within the
normal range. The slightly-high tumors showed poor sur-
vival compared to slightly-low tumors. Likewise, a cluster of
LGGswith very highCGImethylation in theHC-NB group
existed and showed worse survival. The data are not shown
because the current study is focused on pan-cancer compar-
ison and confounding variables are not perfectly controlled.
Furthermore, some tumors like KICH, GBM, ACC and
UCS had limited number of cases. Therefore such hetero-
geneity may be pursued in subsequent studies with tumor-
specific considerations and with more thorough investiga-
tion and control of covariates.
Collectively, we present a pan-cancer model connect-
ing CGI methylation with hypermutability, MSI-H, IDH1
mutation, 19p gain and polycomb proteins and backbone
demethylation with chromosomal instability, NSD1 and
TP53 mutations, 5q and 19p loss and long repressive do-
mains (Figure 5). For therapeutic implications, one could
surmise that demethylating agents could be applied by
considering degrees of CGI methylation and backbone
demethylation in each tumor. Sincemany pathways are sup-
pressed in methylated and demethylated tumors, thought-
ful usage of new targeted drugs inhibiting such pathways is
warranted.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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